The Pennant (US:PNTG)2026-02-26 18:02Financial Data and Key Metrics Changes - The company reported full-year consolidated revenue of $947.7 million, an increase of $252.5 million, or 36.3% year-over-year [8] - Adjusted EBITDA for the full year was $72.5 million, up $19.2 million, or 36% [8] - Adjusted earnings per share for the full year reached $1.18, exceeding the midpoint of the updated annual guidance of $1.16 [7] Business Line Data and Key Metrics Changes - In the home health and hospice segment, Q4 revenue was $233.3 million, an increase of $91.3 million, or 64.3% year-over-year [14] - Adjusted EBITDA for the home health segment in Q4 was $33.7 million, up $12.4 million, or 58.2% [14] - The senior living segment saw full-year revenue improve to $215 million, an increase of $39.2 million, or 22.3% [17] Market Data and Key Metrics Changes - The average daily census in the hospice segment grew to 5,060, a 46.9% increase over the prior year quarter [16] - Same-store Medicare admissions in home health grew by 8.2%, with a 3.7% increase in Medicare revenue per episode [15] - All-store occupancy in the senior living segment rose to 80.6%, with same-store occupancy increasing to 82.1% [18] Company Strategy and Development Direction - The company is focused on optimizing performance and driving operational excellence while remaining open to selective acquisitions [10] - Key focus areas include leadership development, clinical excellence, employee experience, margin improvement, and growth [9] - The company plans to continue expanding its senior living business, with significant growth potential identified [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying trajectory of the business despite reimbursement headwinds [15] - The company anticipates a full-year revenue guidance for 2026 in the range of $1.13 billion to $1.17 billion, reflecting a 22.4% increase at the midpoint [12] - Management highlighted the importance of local leadership in driving growth and maintaining strong clinical outcomes [59] Other Important Information - The company completed two senior living acquisitions in Q4, reinforcing its strategic commitment to expanding high-quality senior care [21][22] - The balance sheet remains strong, with a net debt to adjusted EBITDA ratio of 1.7 times, well under the covenant limit [24] Q&A Session Summary Question: Is the guidance conservative due to the Amedisys/LHCG integration? - Management confirmed that the guidance reflects a conservative approach due to expected initial noise during the transition [32] Question: How do joint ventures perform compared to non-JV agencies? - Management stated that joint ventures are treated like any Pennant business, focusing on local leadership and collaboration with health system partners [34] Question: What are the expectations for the Amedisys UNH asset ramp-up compared to Signature? - Management noted similarities in leadership quality and operational readiness, expressing confidence in the transition process [41] Question: What is the expected same-store revenue growth for 2026? - Management indicated a projected 7% increase in home health and hospice revenue for 2026 [53] Question: What is the competitive backdrop in the hospice segment? - Management highlighted a normalization in growth trends and emphasized the opportunity presented by the aging population [80]